Farglitazar

Chemical compound

ATC code

none

Legal statusLegal status

Development discontinued

Identifiers

IUPAC name

N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine

CAS Number

196808-45-4^Y

PubChem CID

170364

IUPHAR/BPS

2672

ChemSpider

148961^Y

UNII

3433GY7132

KEGG

D04132

ChEMBL

ChEMBL107367^Y

CompTox Dashboard (EPA)

DTXSID1047310

Chemical and physical dataFormulaC₃₄H₃₀N₂O₅Molar mass546.623 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5

InChI

InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1^N
Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N^N

^NY (what is this?) (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.^[1] After reaching phase III for type 2 diabetes, further development was discontinued.^[2]^[3]

References

^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
^ "Farglitazar". pharmacodia.com.